Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 25, Issue 2, 2006, Pages 98-103

  De Larranaga G F ^a   Peres Wingeyer S D A ^a   Puga, L M ^a   Alonso, B S ^a   Benetucci, J A ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLUCOSE; INSULIN; PADGEM PROTEIN; PROTEINASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIUM; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE ACTIVATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; MULTIVARIATE ANALYSIS; P-SELECTIN; PLATELET ACTIVATION; VASCULAR CELL ADHESION MOLECULE-1; VIRAL LOAD; VON WILLEBRAND FACTOR;

EID: 33644668714     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-006-0090-6     Document Type: Article

References (35)

1. Grunfeld C, Tien P (2003) Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 37 (Suppl 2):S43-S46
2. Powderly WG (2002) Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 29 (Suppl 1):S28-S40
3. Carr A (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17 (Suppl 1):s141-s148
4. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chishol DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093-2099
5. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M (2000) Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23:35-43
6. Dubé MP, Johnson DL, Currier JS, Leedom JM (1997) Protease inhibitor-associated hyperglycaemia. Lancet 350:713-714
7. Botella JI, Valero MA, Muñoz V, Hurtado A, Varela C (2000) Complete resolution of protease inhibitor induced diabetes mellitus. Clin Endocrinol 52:241-250
8. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13:805-810
9. Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW (2003) HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 52:1695-1700
10. Grinspoon S (2003) Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 37 (Suppl 2):S85-S90
11. Andersen O, Haugaard SB, Andersen UB, Friis-Møller N, Storgaard H, Vølund A, Nielsen JO, Iversen J, Madsbad S (2003) Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in β-cell function. Metabolism 52:1343-1353
12. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527-3561
13. Blann AD, Seigneur M, Steiner M, Miller IP, McCollum CN (1998) Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking and in the prediction of adverse events. Thromb Haemost 79:1080-1085
14. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104:1336-1342
15. de Larrañaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA (2002) Viral load and disease progression as responsible for endothelial activation and/or injury in HIV-1 infected patients. Blood Coag Fibrinol 14:15-18
16. Konrad T, Zeuzem S, Toffolo G, Vicini P, Teuber G, Briem D, Lormann J, Lenz T, Herrmann G, Berger A, Cobelli C, Usadel KH (2000) Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion 62:52-59
17. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592-599
18. Mehta SH, Strathdee SA, Thomas DL (2001) Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev 23:302-312
19. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, Wood KC, Holmberg SD, and the HIV Outpatients Study Investigators (2003) Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36:363-367
20. Klein MB, Lalonde RG, Suissa S (2003) The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33:365-372
21. Pérez-Cano R, Fernández-Gutiérrez C, López-Suárez A, Mira J, Girón-González JA (2002) Factors related to the chronicity and evolution of hepatitis C infection in patients co-infected by the human immunodeficiency virus. Clin Microbiol Infect 8:589-597
22. Sterling RK, Contos MJ, Sanyal AJ, Luketic VA, Stravitz RT, Wilson MS, Mills AS, Shiffman ML (2003) The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 32:30-37
23. Howard AA, Klein RS, Schoenbaum EE (2003) Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drugs users. Clin Infect Dis 36:1318-1323
24. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS (2003) The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 33:577-584
25. Macias J, Pineda JA, Lozano F, Corzo JE, Ramos A, León E, García-García JA, Fernández-Rivera J, Mira JA, Gómez-Mateo J (2003) Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis 22:675-680
26. Jenny-Avital ER (2003) HCV-coinfection is associated with diabetes and CD4 decline. AIDS Clin Care 15:103
27. Den Brinker M, With FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM (2000) Hepatitis B and C co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14:2895-2902
28. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A (2003) Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 33:146-152
29. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K (2004) Hepatitis C virus infection and diabetes: involvement of the virus in the development of insulin resistance. Gastroenterology 126:840-848
30. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H (2001) Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Syndr 27:245-250
31. Pober JS (1988) Cytokine-mediated activation of vascular endothelium. Am J Pathol 133:426-433
32. Blann A, Seigneur M (1997) Soluble markers of endothelial cell function. Clin Hemorheol 17:3-11
33. Kaplanski G, Farnarier C, Payan MJ, Bongrand P, Durand JM (1997) Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Dig Dis Sci 42:2277-2284
34. de Larrañaga G, Galich A, Puga L, Alonso B, Benetucci J (2004) Insulin resistance status is an important determinant of PAI-1 levels in HIV infected patients, independently of the lipid profile. J Thromb Haemost 2:532-534
35. Kim SH, Abbasi F, Reaven GM (2004) Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 27:1998-2002